Literature DB >> 14712314

Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence.

Rui He1, Bin Liu, Chen Yang, Ren Chi Yang, Gerard Tobelem, Zhong Chao Han.   

Abstract

Vascular endothelial growth factor (VEGF), a major angiogenic factor, plays a key role in the growth of solid tumor. Recently, expression of VEGF and its receptors has been found on leukemic cells as well as on endothelial cells. VEGF may fulfill a fundamental role in promoting tumor angiogenesis and proliferation by stimulating both endothelial cells and leukemic cells. To investigate the role of VEGF in the angiogenesis and growth of leukemic cell, we used an antisense strategy to downregulate VEGF expression in K562 cells, a human erythroleukemia cell line. Expression of antisense-VEGF in K562 cells reduced the secretion of VEGF protein and inhibited cell survival. The proliferation and migration of human umbilical vein endothelial cells were decreased in response to the conditioned medium (CM) from K562 cells expressed antisense-VEGF, compared to CM from K562 cells transfected with vector control. Moreover, subcutaneous injection of nude mice with antisense-VEGF K562 cells inhibited tumor growth with a reduction of the density of microvessels and an increased apoptosis in those tumors, compared to vector control K562 cells. These results suggest that the efficient downregulation of the VEGF production in leukemic cells using antisense-VEGF may constitute a novel strategy of treatment in leukemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14712314     DOI: 10.1038/sj.cgt.7700645

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  7 in total

1.  Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

Authors:  Kevin A Goncalves; Guo-Fu Hu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-23

2.  Expression of vascular endothelial growth factor in normal, osteoarthritic and osteoporotic osteoblasts.

Authors:  Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2011-11-29       Impact factor: 3.984

3.  Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia.

Authors:  Misti Samaiya; Sameer Bakhshi; Abhay A Shukla; Lalit Kumar; Shyam S Chauhan
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

4.  Reduced miR-16 levels are associated with VEGF upregulation in high-risk myelodysplastic syndromes.

Authors:  Bei Xiong; Yanbo Nie; Yalan Yu; Shixuan Wang; Xuelan Zuo
Journal:  J Cancer       Date:  2021-01-30       Impact factor: 4.207

5.  Apoptotic and Cell Cycle Effects of Triterpenes Isolated from Phoradendron wattii on Leukemia Cell Lines.

Authors:  Lía S Valencia-Chan; Dafné Moreno-Lorenzana; Jimmy Josué Ceballos-Cruz; Sergio R Peraza-Sánchez; Antonieta Chávez-González; Rosa E Moo-Puc
Journal:  Molecules       Date:  2022-08-31       Impact factor: 4.927

6.  Soluble Flt-1 gene delivery in acute myeloid leukemic cells mediating a nonviral gene carrier.

Authors:  Razieh Amini; Farid Azizi Jalilian; Abhi Veerakumarasivam; Syahril Abdullah; Ahmed S Abdulamir; Fatemeh Nadali; Rozita Rosli
Journal:  Biomed Res Int       Date:  2013-01-10       Impact factor: 3.411

7.  Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells.

Authors:  David Muench; Francine Rezzoug; Shelia D Thomas; Jingjing Xiao; Ashraful Islam; Donald M Miller; Kara C Sedoris
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.